Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)

BACKGROUND: The effect of ezetimibe, Niemann-Pick C1-like 1 inhibitor, on liver fat is not clearly elucidated. Our primary objective was to evaluate the efficacy of ezetimibe plus rosuvastatin versus rosuvastatin monotherapy to reduce liver fat using magnetic resonance imaging-derived proton density...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Yongin, Rhee, Hyungjin, Kim, Young-eun, Lee, Minyoung, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo, Choi, Jin-Young, Lee, Yong-ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935785/
https://www.ncbi.nlm.nih.gov/pubmed/35307033
http://dx.doi.org/10.1186/s12916-022-02288-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935785/
https://www.ncbi.nlm.nih.gov/pubmed/35307033
http://dx.doi.org/10.1186/s12916-022-02288-2

Ejemplares similares